Skip to main content
Premium Trial:

Request an Annual Quote

Seegene Signs Japan Marketing Deal with Eidia

NEW YORK (GenomeWeb News) – Seegene announced today that it has signed an agreement with Eidia to market the firm's molecular diagnostic products in Japan.

Under the deal, Eidia, which is the diagnostics subsidiary of Eisai, will have access to Seegene's TOCE (tagging oligonucleotide capture and extension) multiplex molecular diagnostic tests. The Japanese firm will exclusively market and distribute the tests in Japan, and it will seek regulatory clearance from the Japanese Pharmaceutical and Medical Device Agency.

"Our partnership with Eidia opens a significant sales channel for our novel diagnostic tests in Japan," Jong-Yoon Chun, founder, CTO, and CEO of Seegene, said in a statement. "We look forward to working with Eidia to improve patient healthcare with highly sensitive and specific multiplexed MoDx tests."

Further terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.